| Literature DB >> 24055391 |
Renata Tavares Gomes1, Ticiana Goyanna Lyra, Noraney Nunes Alves, Renilza Menezes Caldas, Maria-Goreth Barberino, Cristiana Maria Nascimento-Carvalho.
Abstract
Methicillin-resistant Staphylococcus aureus has emerged as a pathogen associated with community-acquired infections worldwide. We report the spectrum of community-acquired S. aureus infections and compare the patients infected with methicillin-susceptible or methicillin-resistant strains among patients aged <20 years. Overall, 90 cases of community-acquired S. aureus were detected in an 11-year period. Clinical and microbiological data were registered. Fifty-nine (66%) patients were male and the median age was two years. The majority (87%) of the patients were hospitalized and chronic underlying illnesses were detected in 27 (30%) cases. Overall, 34 (37.8%) patients had skin/soft tissue infections and 56 (62.2%) patients had deep-seated infection. Four (5.1%) patients were transferred to the intensive care unit and two (2.6%) died. Complications were detected in 17 (18.9%) cases, such as pleural effusion (41.2%), osteomyelitis (23.5%), and sepsis (17.6%). Six (6.7%) methicillin-resistant strains were detected. Patients infected with methicillin-susceptible or methicillin-resistant strains had similar baseline characteristics and treatment outcomes. Approximately 93% of the cases received systemic antibiotics, out of which 59 (65.5%) used oxacillin or cefalotin. Both methicillin-susceptible and methicillin-resistant S. aureus strains resulted in morbidity and death among children in this setting where methicillin-resistant strains are infrequent.Entities:
Keywords: Antibacterial agents; Community-acquired infection; Methicillin resistance; Staphylococcal infections; Staphylococcus aureus antimicrobial resistance
Mesh:
Substances:
Year: 2013 PMID: 24055391 PMCID: PMC9425138 DOI: 10.1016/j.bjid.2013.02.010
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Comparison of patients with community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus infection.
| Characteristic | MRSA ( | MSSA ( | |
|---|---|---|---|
| 2 (33.3) | 57 (67.9) | 0.2 | |
| <2 years | 4 (66.7) | 41 (48.8) | 0.7 |
| Median (25th–75th percentile) | 5.4 mo (16d–5.1yr) | 26.4 mo (6.5 mo–6.3yr) | 0.2 |
| 6 (100) | 72 (85.7) | 1 | |
| 4 (66.7) | 23 (27.4) | 0.06 | |
| Skin | 1 (16.7) | 11 (13.1) | 0.6 |
| Heart | 1 (16.7) | 6 (7.1) | 0.4 |
| Respiratory tract | 0 | 3 (3.6) | 1 |
| 2 (33.3) | 10 (11.9) | 0.2 | |
| 6 (100) | 50 (59.5) | 0.08 | |
| 5 (83.3) | 61 (72.6) | 1 | |
| Death | 1 (16.7) | 1 (1.2) | 0.1 |
| Intensive care unit | 1 (16.7) | 3 (4.1) | 0.3 |
| Length of hospitalization (days) | 16 ± 11 | 16 ± 12 | 1 |
| Complications | 1 (16.7) | 16 (19) | 1 |
| Vancomycin use | 2 (33.3) | 10 (11.9) | 0.2 |
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
Results in n (%).
Patients with community-acquired methicillin-resistant S. aureus bacteremia without vancomycin use.
| Characteristic | Case I | Case II | Case III | Case IV |
|---|---|---|---|---|
| 8 May 1996 | 18 September 1996 | 2 August 2004 | 10 October 2005 | |
| 14 days | 16 days | 36 months | 5 months | |
| Female | Female | Female | Male | |
| None | Congenital heart disease | Sickle cell disease | None | |
| Pneumonia | Pneumonia | Dactylitis | Pyodermitis | |
| No | No | No | No | |
| Cep & Ami | Pen G & Ami | None | Oxa | |
| None | Oxa | None | None | |
| 19 | 12 | 7 | 15 | |
| None | None | None | None | |
| Resolution | Resolution | Resolution | Resolution | |
| Susceptible | Ami, Cip, Tei | Gen, Rif, Tei, TMP-SMX, Van | Ami, Cip, Cli, Ery, Gen, Rif, Tei, Van | Ami, Cip, Ery, Gen, Tei, TMP-SMX, Van |
| Resistant | Ery, Gen | Ami, Ery | TMP-SMX | – |
Ami, amikacin; Cep, cefalotin; Cip, ciprofloxacin; Cli, clindamycin; Ery, erythromycin; Gen, gentamicin; Oxa, oxacillin; Pen G, aqueous penicillin G; Rif, rifampin; Tei, teicoplanin; TMP-SMX, trimethoprim-sulfamethoxazole; Van, vancomycin.